| Name | Title | Contact Details |
|---|
Fair. Rude. But fair. Lets take the second question first. In competitive cycling, Domestiques are riders who lead the pack, breaking headwinds to make the journey easier for the team. And its the love of doing the hard, foundational, gritty and unglamorous work that informs everything we do. Now, to your first question. Domestique is a management consultant company that helps businesses scale through go-to-market operations (aka Revenue Operations or RevOps). Not sure what that answer means? No sweat. We, in the next paragraph. will make it as long-winded as possible. We are Rhys Williams and Alex Biale, co-founders of Domestique. We have a combined 25+ years in go-to-market operations experience, translating CEO questions like "lets move up market" and "lets expand internationally" into best-in-class operations. Our expertise informed the development of a GTM operational framework that we use to help companies create, accelerate and optimize their revenue engines. And our understanding of building, scaling, funding and preparing your company for exit is what sets our expertise apart. Our mission? Empower your business to unlock growth levers to do great things. (What are growth levers? Theyre things like Capacity Planning, Lead Scoring, Customer Segmentation, Comp Strategy, and other terms that sound like things we just made up). Growing a business is hard and too often companies fail because they lack the preparation, agility and connective tissue to get through the hard part. We help by though strategic and technical services to align your business strategy with your go-to-market playbook. Because visualizing your goals, your outcomes and life-changing moments—thats where you come in. Getting you from mile marker to mile marker—thats where we come in. After all, thats our role as your Domestique—Your accelerator. Your guide. Your teammate.
Synonym is accelerating the worlds biological future by developing, financing and building commercial-scale biomanufacturing facilities. We provide synthetic biology (synbio) producers – from startups to the Fortune 500 – with flexible production capacity while giving infrastructure investors access to a new, carbon-negative biomanufacturing asset class that we are calling "fermentation farms".
Continental Generals mission is to assist our customers with managing the financial risks and challenges that come as they age. Our skills, resources, and infrastructure allow us to help them with insulating and enhancing retirement income and maneuvering caregiving options. Thus allowing us to responsibly be a part of the solution rather than the problem. Our team of long-term care industry experts, with headquarters in Austin, Texas, strives to build value through superior operating results. As we manage our current portfolio of business, we continue to pursue growth opportunities for expansion and economies of scale through strategic acquisitions, mergers, and reinsurance opportunities. Our family of insurance companies and strategic partners provide administrative services to approximately 125,000 Long-Term Care, Life, Annuity and Supplemental Health customers. We are dedicated to upholding the commitments we have made to provide excellent service to all our customers and serve the needs of our claimants and their families during difficult times.
MotoRad Ltd. is a global manufacturer of automotive components, specializing in thermal management systems. Established in 1958 and originally known as Fishman Engineering Ltd., the company is now owned by Fortissimo Investment Funds and employs 156 people. In 2025, MotoRad reported an annual revenue of $28.7 million, with Matt Buchholz serving as CEO. The company develops and manufactures a range of thermal management solutions, including thermostats, caps, and sensors. These products are designed for internal combustion engines, hybrid vehicles, plug-in hybrids, and battery electric vehicles. MotoRad serves automotive OEMs, aftermarket distributors, and industrial applications, ensuring a high level of product availability and a 97.81% global fill rate to meet customer needs. The company emphasizes innovation and collaborative work environments, focusing on employee development and technological advancement.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.